Changes in tumor blood flow as estimated by dynamic-contrast MRI may predict activity of single-agent bevacizumab in recurrent epithelial ovarian cancer and primary peritoneal cancer: An exploratory analysis of a Gynecologic Oncology Group phase II trial

✍ Scribed by D. Chase; M. Sill; M. Chambers; K. Darcy; E. Han; J. Fruehauf; B. Monk; B. Buening; J. Sorosky; R. Burger

• Book ID: 113962880
• Publisher: Elsevier Science
• Year: 2011
• Tongue: English
• Weight: 124 KB
• Volume: 120
• Category: Article
• ISSN: 0090-8258
• DOI: 10.1016/j.ygyno.2010.12.157